Nucleic Acid Therapeutics CDMO Market Size & Growth Forecast 2027–2036, By Segments (Type, End-use, Service, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Nucleic Acid Therapeutics CDMO Market size was valued at USD 19.8 billion in 2026 and is anticipated to grow at a 13.78% CAGR from 2027 to 2036, surpassing USD 72 billion by 2036. The industry revenue for 2027 is assessed at USD 22.1 billion.
Get more details on this report
Request Free Sample ReportNucleic Acid Therapeutics CDMO Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 42.61% share due to strong CDMO base, advanced biopharma outsourcing, and mature regulatory systems supporting complex nucleic acid manufacturing and scale-up needs.
- Asia Pacific is growing at 15.79% CAGR driven by rising outsourcing demand, expanding manufacturing capacity, and increasing adoption of cost-efficient and scalable CDMO services.
Segment Momentum
- RNA-based Therapies held a 63.68% market share in 2026 because developers depend on CDMOs for specialized process development, analytical support, and scalable manufacturing across complex RNA production workflows.
- Government and academic research institutes are growing fastest as they increasingly rely on CDMOs to transform early-stage nucleic acid discoveries into clinically usable materials without building commercial manufacturing infrastructure.
Market Expansion Drivers
- Rapid expansion of RNA and gene therapy pipelines driving outsourced manufacturing demand.
- Increasing prevalence of genetic disorders accelerating demand for personalized nucleic acid therapies.
- Growing adoption of one-stop CDMO models improving end-to-end biologics development efficiency.
Leading Market Participants
- Top players in the nucleic acid therapeutics CDMO market include WuXi AppTec Co., Ltd. (China), Danaher Corporation (United States), Merck KGaA (Germany), Curia Global, Inc. (United States), Agilent Technologies, Inc. (United States), Ajinomoto Co., Inc. (Japan), LGC Limited (United Kingdom), BioSpring GmbH (Germany), Exothera S.A. (Belgium), KNC Laboratories Co., Ltd. (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 19.8 billion
- 2027 Estimated Market Size: USD 22.1 billion.
- Projected Market Size: USD 72 billion by 2036
- Growth Forecast: 13.78% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: RNA-based Therapies (Type) | Biotech Companies (End-use) | Manufacturing Services (Service) | Infectious Diseases (Application)
- Emerging Opportunity Segment: Gene Therapy (Type) | Government & Academic Research Institutes (End-use) | Process Development and Optimization (Service) | Infectious Diseases (Application)
Market Growth Drivers and Industry Trends
Rapid expansion of RNA and gene therapy pipelines driving outsourced manufacturing demand
The expansion of RNA-based and gene therapy development programs is creating increasingly specialized manufacturing requirements that can be difficult for developers to address entirely through internal infrastructure. The nucleic acid therapeutics CDMO market will grow as developers outsource production, process development, analytical testing, and related manufacturing activities to specialized partners. External manufacturing providers can offer technical capabilities and production infrastructure suited to complex nucleic acid modalities, allowing therapy developers to focus internal resources on research and clinical development activities.
Increasing prevalence of genetic disorders accelerating demand for personalized nucleic acid therapies
A growing focus on genetic disorders is strengthening interest in therapies designed to address disease mechanisms at the genetic or molecular level. This trend will support the nucleic acid therapeutics CDMO market as developers pursue RNA and gene-based approaches tailored to specific disease characteristics and patient populations. Personalized therapeutic strategies can require specialized development and manufacturing processes, increasing the need for CDMOs capable of adapting production workflows and analytical methods to different nucleic acid-based treatment programs.
Growing adoption of one-stop CDMO models improving end-to-end biologics development efficiency
Developers are increasingly seeking integrated outsourcing arrangements that can connect multiple stages of therapeutic development rather than relying on separate service providers for individual activities. One-stop models will strengthen the nucleic acid therapeutics CDMO market by allowing sponsors to coordinate development, analytical, manufacturing, and related support activities through a more integrated workflow. Consolidating these functions can reduce handoffs between providers and improve coordination across development stages, particularly for complex nucleic acid therapies requiring specialized processes from early development through manufacturing.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rapid expansion of RNA and gene therapy pipelines driving outsourced manufacturing demand | 2.00% | High | North America, Europe | High | Near Term |
| Increasing prevalence of genetic disorders accelerating demand for personalized nucleic acid therapies | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Growing adoption of one-stop CDMO models improving end-to-end biologics development efficiency | 1.50% | Moderate | Europe, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
Holding a 42.61% share in 2026, North America led the nucleic acid therapeutics CDMO market due to its advanced biopharmaceutical ecosystem, substantial research activity, and strong capabilities in complex therapeutic development and manufacturing. The region benefits from extensive investment in biotechnology innovation and well-developed infrastructure for process development, analytical testing, and specialized production of nucleic acid-based therapies. Growing demand for outsourced expertise, combined with the need for scalable and high-quality manufacturing capabilities, continues to support North America's prominent market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to be the fastest-growing region, supported by expanding biopharmaceutical manufacturing capacity, rising investment in advanced therapeutic technologies, and increasing efforts to strengthen domestic life sciences capabilities. The region is attracting greater interest in outsourced development and manufacturing services as healthcare innovation accelerates and production infrastructure becomes more sophisticated. Improving technical expertise, supportive investment environments, and the growing focus on RNA- and other nucleic acid-based therapeutic development are expected to drive the region's market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
GMP Manufacturing ExpertiseGermany prioritizes high-quality GMP manufacturing, analytical characterization, and process optimization for nucleic acid therapeutics. German CDMOs continue expanding specialized production capabilities to support clinical and commercial development of advanced genetic medicines.
France 🇫🇷
Integrated Analytical SupportFrance combines specialized analytical testing with process development services for nucleic acid therapeutics manufacturing. French CDMOs focus on helping developers accelerate product development through robust quality systems and regulatory-ready manufacturing operations.
Italy 🇮🇹
Process Development FocusItaly supports nucleic acid therapeutics CDMO services through expertise in formulation development, process optimization, and pharmaceutical manufacturing. Italian providers continue strengthening technical capabilities that improve production efficiency for innovative genetic therapies.
Japan 🇯🇵
High-Purity ProductionJapan advances nucleic acid therapeutics manufacturing by emphasizing production consistency, impurity control, and process reliability. Japanese CDMOs support pharmaceutical innovators with specialized expertise in complex oligonucleotide manufacturing and quality assurance.
South Korea 🇰🇷
Flexible Development CapacitySouth Korea is expanding CDMO capabilities for nucleic acid therapeutics through investments in modular manufacturing facilities and advanced production technologies. South Korean providers increasingly attract biotechnology companies requiring responsive process development and scalable manufacturing services.
United States 🇺🇸
End-to-End ManufacturingThe U.S. nucleic acid therapeutics CDMO market focuses on integrated development and manufacturing for mRNA, siRNA, antisense oligonucleotides, and gene-editing platforms. U.S. customers increasingly seek scalable production, analytical testing, and regulatory support from specialized CDMO partners.
Segment Leadership and Growth Trends
Nucleic Acid Therapeutics CDMO Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: RNA-based Therapies (Largest Segment) vs Gene Therapy (Fastest-Growing Segment)
RNA-based therapies held the largest share of the nucleic acid therapeutics CDMO market at 63.68% in 2026, supported by expanding development activity around RNA modalities and the need for specialized manufacturing capabilities. Production of RNA-based therapeutics requires controlled processes, specialized analytical expertise, and stringent quality management, encouraging developers to use CDMO partners with established technical capabilities. Continued interest in RNA-driven therapeutic approaches is sustaining demand for outsourced development and manufacturing services.
Gene therapy is the fastest-growing segment, driven by increasing efforts to develop treatments that address diseases at the genetic level. The complexity of vector development, production, analytical testing, and quality control creates significant demand for specialized CDMO support. As research programs advance toward clinical development, the need for scalable and technically sophisticated manufacturing capabilities is strengthening outsourcing opportunities in this segment.
End-use Segment Analysis: Biotech Companies (Largest Segment) vs Government & Academic Research Institutes (Fastest-Growing Segment)
Biotech companies represented the largest end-use segment of the nucleic acid therapeutics CDMO market in 2026, reflecting their strong reliance on external partners for specialized development and manufacturing activities. Many biotechnology developers prioritize research and therapeutic innovation while using CDMOs to access technical infrastructure, manufacturing expertise, and quality systems without maintaining extensive internal production capabilities. Increasing development of nucleic acid-based therapeutics continues to support sustained outsourcing demand from this customer group.
Government and academic research institutes are emerging as the fastest-growing end-use segment as public research programs increasingly explore nucleic acid technologies for innovative therapeutic applications. Greater translation of academic discoveries into development programs is creating demand for specialized manufacturing and development support. Access to external technical capabilities also enables research institutions to progress promising candidates beyond laboratory-stage development while managing resource constraints.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Gene Therapy, RNA-based Therapies | RNA-based Therapies | Gene Therapy |
| End-use | Pharmaceutical Companies, Government & Academic Research Institutes, Biotech Companies | Biotech Companies | Government & Academic Research Institutes |
| Service | Process Development and Optimization, Manufacturing Services, Analytical and Quality Control Services, Others | Manufacturing Services | Process Development and Optimization |
| Application | Rare Diseases, Genetic Disorders, Infectious Diseases, Others | Infectious Diseases | Infectious Diseases |
Competitive Landscape and Market Positioning
Major players in the nucleic acid therapeutics CDMO market:
1. WuXi AppTec Co. Ltd. (China)
2. Danaher Corporation (United States)
3. Merck KGaA (Germany)
4. Curia Global Inc. (United States)
5. Agilent Technologies Inc. (United States)
6. Ajinomoto Co. Inc. (Japan)
7. LGC Limited (United Kingdom)
8. BioSpring GmbH (Germany)
9. Exothera S.A. (Belgium)
10. KNC Laboratories Co. Ltd. (Japan)
The nucleic acid therapeutics CDMO market is advancing through rapid scaling of specialized manufacturing capabilities tailored for next-generation genetic therapies. Strong emphasis on process optimization and advanced biologics production is enabling improved efficiency and regulatory readiness. The nucleic acid therapeutics CDMO market is expanding as demand grows for complex molecular therapeutics and precision medicine solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| WuXi AppTec Co. Ltd. (China) | |||||||
| Danaher Corporation (United States) | |||||||
| Merck KGaA (Germany) | |||||||
| Curia Global Inc. (United States) | |||||||
| Agilent Technologies Inc. (United States) | |||||||
| Ajinomoto Co. Inc. (Japan) | |||||||
| LGC Limited (United Kingdom) | |||||||
| BioSpring GmbH (Germany) | |||||||
| Exothera S.A. (Belgium) | |||||||
| KNC Laboratories Co. Ltd. (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Hongene Biotech | Sep-25 | Hongene Biotech secured a non-exclusive licensing agreement with UMass Chan Medical School to supply exNA monomers and modified oligonucleotides. This deal expands Hongene’s RNA chemistry CDMO portfolio, allowing it to support the development of next-generation RNA therapeutics beyond liver-targeted applications, including tissue-specific delivery platforms that require enhanced chemical stability. |
| Cohance Lifesciences | Aug-25 | Cohance Lifesciences invested USD 2.8 million in a new cGMP oligonucleotide building block facility in Hyderabad. The facility adds 700 kg of annual capacity for modified nucleosides and locked nucleic acids (LNAs), strengthening the company's global CRDMO platform and supporting the supply chain needs of developers working on next-generation RNA-based therapeutics. |
| Sumitomo Chemical | Apr-25 | Sumitomo Chemical established a new US-based CRO and CDMO operation to specialize in large-scale, high-purity guide RNA (gRNA) production. This investment directly supports the rapidly growing genome editing and CRISPR-based therapy market, providing the technical scale and purity standards required for commercial-grade manufacturing of gene-editing components. |
| Agilent Technologies | Jul-24 | Agilent completed its USD 925 million acquisition of BioVectra, substantially expanding its oligonucleotide and CRISPR CDMO capabilities. The acquisition adds significant manufacturing scale across siRNA, antisense, mRNA, and lipid nanoparticle modalities, positioning Agilent as a comprehensive partner for the full-cycle development and fill-finish production of complex nucleic acid and gene-based medicines. |
| AGS Biologics | Mar-24 | AGS Biologics received FDA commercial manufacturing clearance for its Milan site to produce Orchard Therapeutics’ Lenmeldy, a gene therapy for metachromatic leukodystrophy. This milestone demonstrates the company’s capacity to handle the complex, end-to-end manufacturing requirements of commercial-stage gene therapy products, highlighting the growing role of CDMOs in the delivery of transformative autologous cell-based treatments. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Nucleic Acid Therapeutics CDMO Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Manufacturing Scale | Clinical-Scale Manufacturing, Commercial-Scale Manufacturing, Small-Batch & Personalized Manufacturing |
| Manufacturing Platform | Oligonucleotide Manufacturing, Plasmid DNA Manufacturing, mRNA Manufacturing, Other Nucleic Acid Platforms |
| Development Stage | Preclinical Development, Clinical Development, Commercial Manufacturing |
Nucleic Acid Therapeutics CDMO Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Oligonucleotide and mRNA Manufacturing Capacity Assessment |
|
| Technology Platform Differentiation Benchmark |
|
| Strategic Partner Selection Framework for Biopharma Clients |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the nucleic acid therapeutics CDMO market?
How much is the nucleic acid therapeutics CDMO industry expected to grow by 2036?
Why is outsourcing becoming increasingly important in the nucleic acid therapeutics CDMO market?
How are integrated one-stop CDMO models influencing sponsor preferences?
Why are RNA-based Therapies the largest segment in the nucleic acid therapeutics CDMO market?
Why are Government & Academic Research Institutes the fastest-growing end-use segment?
Why does North America lead the nucleic acid therapeutics CDMO market?
What is driving Asia Pacific growth in the nucleic acid therapeutics CDMO market?
Which companies are driving growth in the nucleic acid therapeutics CDMO landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization